Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ZYKADIA
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ZYKADIA

Medicine - Posted on Mar 22 2021
Active substance (DCI)
  • céritinib
history (5)
  • 3/3/21

    ZYKADIA - CBNPC (céritinib)

    Key points Favourable opinion for maintenance of reimbursement in the treatment of adult patients with anaplastic lymphoma k...
    CAV :
    54321
    icône flèche
  • 10/17/18

    ZYKADIA (céritinib)

    Remplacement de la posologie à 750 mg/jour à jeun par 450 mg/jour avec de la nourriture. ...
    icône flèche
  • 10/17/18

    ZYKADIA (céritinib)

    Mise à disposition d’une présentation en boîte de 90 gélules en complément de la boîte de 150 gélules déjà disponible. ...
    CAV :
    54321
    icône flèche
  • 12/13/17

    ZYKADIA (ceritinib), tyrosine kinase inhibitor

    High clinical benefit and minor clinical added value compared to chemotherapy combining a platinum salt and pemetrexed, foll...
    CAV :
    54321
    icône flèche
  • 10/7/15

    ZYKADIA (ceritinib), tyrosine kinase inhibitor

    Minor improvement in the treatment of adults with ALK+ advanced non-small cell lung cancer previously treated with crizotini...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XE28
Manufacturer
NOVARTIS PHARMA S.A.S.
Presentation

ZYKADIA 150 mg, gélule (code CIS : 66958808)
15 plaquette(s) thermoformée(s) PVC polychlortrifluoroéthylène aluminium de 10 gélule(s) (CIP : 34009 300 156 9 8)
Plaquette(s) thermoformée(s) PVC polychlortrifluoroéthylène aluminium de 90 gélule(s) (CIP : 34009 301 461 1 8)

All our publications
    Drug therapy Respiratory tract cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
s5hP1Uw2HQvL8KQp